Liqun He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liqun He has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Feng Yi
Department of Cardiology, Wuhan No. 1 Hospital, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, China
2 shared publications Dong Wang
Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publicationsHongru Fan
Department of Cardiology, Wuhan NO.1 Hospital
2 shared publications- Jiangtao Yan
Department of Cardiology, Wuhan No. 1 Hospital, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, China
2 shared publications - Beilei Liu
Department of Cardiology, Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Chinese Medicine, 431799 Wuhan, Hubei, China
1 shared publication Bin Li
Department of Cardiology, Xianning Central Hospital , Xianning
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1762185
The prognostic value of triglyceride glucose–waist height ratio index in patients with heart failure after acute myocardial infarction: a retrospective study
Background: Heart failure (HF) after acute myocardial infarction (AMI) remains a major clinical challenge. The triglyceride glucose-waist-to-height ratio (TyG-WHtR) integrates metabolic and obesity indices, yet its prognostic value for AMI-HF is unclear. Methods: This retrospective study enrolled 738 AMI patients undergoing PCI from January 2019 to June 2024. Baseline TyG-WHtR was calculated pre-discharge. The primary outcome was HF occurrence within 1-year follow-up. Multivariate logistic regression and restricted cubic splines (RCS) assessed associations. Receiver operating characteristic (ROC) curves and DeLong tests compared TyG-WHtR against the GRACE score and other metabolic indices. Subgroup analyses were performed based on AMI-to-PCI time and ESC-defined HF classifications. Results: A total of 136 patients (18.4%) developed HF. TyG-WHtR was an independent predictor of AMI-HF (adjusted OR = 1.192, 95% CI: 1.021∼1.392, p = 0.026), persisting after adjusting for the post-PCI GRACE score. RCS revealed a positive nonlinear dose-response relationship (p-nonlinear=0.034). TyG-WHtR demonstrated good discrimination (AUC=0.769, 95% CI: 0.726∼0.811), outperforming TyG-WC and TyG-BMI (both p < 0.05). Notably, TyG-WHtR showed superior predictive value in HFpEF (AUC=0.815) compared to GRACE (AUC=0.761, p = 0.012), whereas GRACE performed better in HFrEF. The predictive value was consistent across AMI-to-PCI time strata (p-interaction=0.584). Baseline TyG-WHtR correlated inversely with 1-year LVEF (r = −0.327, p < 0.001) in HF patients. Conclusion: TyG-WHtR is an independent risk factor for 1-year AMI-HF, particularly in HFpEF phenotypes. It provides incremental prognostic value beyond the GRACE score and may guide early risk stratification in post-PCI AMI patients.
- 12 August 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1762185
Open AccessThe prognostic value of triglyceride glucose–waist height ratio index in patients with heart failure after acute myocardial infarction: a retrospective study
Background: Heart failure (HF) after acute myocardial infarction (AMI) remains a major clinical challenge. The triglyceride glucose-waist-to-height ratio (TyG-WHtR) integrates metabolic and obesity indices, yet its prognostic value for AMI-HF is unclear. Methods: This retrospective study enrolled 738 AMI patients undergoing PCI from January 2019 to June 2024. Baseline TyG-WHtR was calculated pre-discharge. The primary outcome was HF occurrence within 1-year follow-up. Multivariate logistic regression and restricted cubic splines (RCS) assessed associations. Receiver operating characteristic (ROC) curves and DeLong tests compared TyG-WHtR against the GRACE score and other metabolic indices. Subgroup analyses were performed based on AMI-to-PCI time and ESC-defined HF classifications. Results: A total of 136 patients (18.4%) developed HF. TyG-WHtR was an independent predictor of AMI-HF (adjusted OR = 1.192, 95% CI: 1.021∼1.392, p = 0.026), persisting after adjusting for the post-PCI GRACE score. RCS revealed a positive nonlinear dose-response relationship (p-nonlinear=0.034). TyG-WHtR demonstrated good discrimination (AUC=0.769, 95% CI: 0.726∼0.811), outperforming TyG-WC and TyG-BMI (both p < 0.05). Notably, TyG-WHtR showed superior predictive value in HFpEF (AUC=0.815) compared to GRACE (AUC=0.761, p = 0.012), whereas GRACE performed better in HFrEF. The predictive value was consistent across AMI-to-PCI time strata (p-interaction=0.584). Baseline TyG-WHtR correlated inversely with 1-year LVEF (r = −0.327, p < 0.001) in HF patients. Conclusion: TyG-WHtR is an independent risk factor for 1-year AMI-HF, particularly in HFpEF phenotypes. It provides incremental prognostic value beyond the GRACE score and may guide early risk stratification in post-PCI AMI patients.
- 16 January 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (1) , e70133
G Protein‐Coupled Receptor Signaling in Atherosclerosis: Mechanistic Insights and Therapeutic Targeting
Atherosclerosis (AS), the primary pathological basis of cardiovascular diseases, is driven by lipid deposition, chronic inflammation, and vascular wall fibrosis. Nevertheless, persistent inflammatory environments and plaque instability remain significant clinical challenges. G protein‐coupled receptors (GPCRs), constituting the largest family of membrane receptors in humans, play a central role in AS progression by modulating macrophage polarization, vascular smooth muscle cells (VSMCs) proliferation and migration, and oxidized low‐density lipoprotein (ox‐LDL) metabolism. Macrophage polarization dictates the inflammatory microenvironment within plaques; GPCRs modulate macrophage phenotypes through downstream signaling pathways, thereby exacerbating or mitigating inflammation. Furthermore, GPCRs regulate VSMCs phenotypic switching, critically influencing the stability of the plaque fibrous cap. Additionally, the interplay between GPCRs and ox‐LDL exacerbates endothelial dysfunction and amplifies inflammatory signaling. This review comprehensively summarizes the roles of GPCR family members in AS pathogenesis and explores targeting these molecules as a promising therapeutic strategy for AS, thus highlighting their potential for multi‐targeted intervention.
- 16 January 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (1) , e70133
G Protein‐Coupled Receptor Signaling in Atherosclerosis: Mechanistic Insights and Therapeutic Targeting
Atherosclerosis (AS), the primary pathological basis of cardiovascular diseases, is driven by lipid deposition, chronic inflammation, and vascular wall fibrosis. Nevertheless, persistent inflammatory environments and plaque instability remain significant clinical challenges. G protein‐coupled receptors (GPCRs), constituting the largest family of membrane receptors in humans, play a central role in AS progression by modulating macrophage polarization, vascular smooth muscle cells (VSMCs) proliferation and migration, and oxidized low‐density lipoprotein (ox‐LDL) metabolism. Macrophage polarization dictates the inflammatory microenvironment within plaques; GPCRs modulate macrophage phenotypes through downstream signaling pathways, thereby exacerbating or mitigating inflammation. Furthermore, GPCRs regulate VSMCs phenotypic switching, critically influencing the stability of the plaque fibrous cap. Additionally, the interplay between GPCRs and ox‐LDL exacerbates endothelial dysfunction and amplifies inflammatory signaling. This review comprehensively summarizes the roles of GPCR family members in AS pathogenesis and explores targeting these molecules as a promising therapeutic strategy for AS, thus highlighting their potential for multi‐targeted intervention.
- Open Access
- 1 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (39) , 3888-3901
Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial
Background and Aims: The beneficial effect of pre-treatment with unfractionated heparin (UFH) at first medical contact (FMC) before primary percutaneous coronary intervention (PPCI) in all-comers with ST-elevation myocardial infarction (STEMI) remains uncertain. Methods: HELP-PCI was an investigator-initiated, randomized controlled trial conducted at 36 clinical centres in China. Patients with STEMI presenting ≤12 h after symptom onset undergoing PPCI were randomly assigned (1:1) to intravenous administration with UFH (100 U/kg) at FMC or in the Cath Lab through a catheter sheath. The primary endpoint was Thrombolysis in Myocardial Infarction flow grade (TFG)-3 of infarct-related artery (IRA) at diagnostic angiography before PPCI. The secondary outcome was complete epicardial and myocardial reperfusion after PPCI and major adverse cardiac and cerebrovascular events (MACCE; defined as the composite of all-cause death, cardiac death, heart failure hospitalizations, re-infarction, stent thrombosis, unplanned revascularization, and stroke) at 12 months. Safety outcome was 30-day Bleeding Academic Research Consortium (BARC) type ≥2 bleeding. Results: A total of 999 patients with STEMI undergoing PPCI were randomly assigned to receive either UFH administration at FMC (n = 505) or in the Cath Lab (n = 494). Pre-treated population at FMC showed a higher frequency of TFG-3 of IRA compared with the Cath Lab group (23.6% vs 17.6%; odds ratio, 1.44; 95% confidence interval, 1.06–1.97; P = .02). There were no significant differences in secondary endpoints or in the safety endpoint, including 12-month MACCE, complete epicardial and myocardial reperfusion, and major bleeding. Conclusions: Pre-treatment with loading-dose UFH at FMC was associated with an improvement of spontaneous reperfusion of IRA without increasing the risk of major bleeding.
- 1 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (39) , 3888-3901
Open AccessHeparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial
Background and Aims: The beneficial effect of pre-treatment with unfractionated heparin (UFH) at first medical contact (FMC) before primary percutaneous coronary intervention (PPCI) in all-comers with ST-elevation myocardial infarction (STEMI) remains uncertain. Methods: HELP-PCI was an investigator-initiated, randomized controlled trial conducted at 36 clinical centres in China. Patients with STEMI presenting ≤12 h after symptom onset undergoing PPCI were randomly assigned (1:1) to intravenous administration with UFH (100 U/kg) at FMC or in the Cath Lab through a catheter sheath. The primary endpoint was Thrombolysis in Myocardial Infarction flow grade (TFG)-3 of infarct-related artery (IRA) at diagnostic angiography before PPCI. The secondary outcome was complete epicardial and myocardial reperfusion after PPCI and major adverse cardiac and cerebrovascular events (MACCE; defined as the composite of all-cause death, cardiac death, heart failure hospitalizations, re-infarction, stent thrombosis, unplanned revascularization, and stroke) at 12 months. Safety outcome was 30-day Bleeding Academic Research Consortium (BARC) type ≥2 bleeding. Results: A total of 999 patients with STEMI undergoing PPCI were randomly assigned to receive either UFH administration at FMC (n = 505) or in the Cath Lab (n = 494). Pre-treated population at FMC showed a higher frequency of TFG-3 of IRA compared with the Cath Lab group (23.6% vs 17.6%; odds ratio, 1.44; 95% confidence interval, 1.06–1.97; P = .02). There were no significant differences in secondary endpoints or in the safety endpoint, including 12-month MACCE, complete epicardial and myocardial reperfusion, and major bleeding. Conclusions: Pre-treatment with loading-dose UFH at FMC was associated with an improvement of spontaneous reperfusion of IRA without increasing the risk of major bleeding.
- Open Access
- 19 February 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (2) , 26268
Stellate Ganglionectomy Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction
Background: Enhanced cardiac sympathetic activity contributes to chronic heart failure (CHF). Interventions targeting the stellate ganglion (SG) can reduce this activity, potentially slowing the progression of cardiovascular diseases. This study examined the effects and mechanisms of stellate ganglionectomy on myocardial hypertrophy and cardiac dysfunction caused by pressure overload. Methods: A rat model of pressure overload was created using abdominal aortic constriction. Four groups were studied: the sham surgery, abdominal aortic coarctation (AB), aortic constriction plus left stellate ganglionectomy (LSG), and aortic constriction plus right stellate ganglionectomy (RSG) groups. Cardiac function was assessed via echocardiography, and myocardial hypertrophy and fibrosis were evaluated using hematoxylin-eosin staining (H&E) and Masson staining. Serum atrial natriuretic peptides (ANP) and norepinephrine (NE) levels were measured using enzyme linked immunosorbent assay (ELISA), and the levels of the molecular markers tyrosine hydroxylase (TH) and growth-associated protein-43 (GAP43) were analyzed using Western blotting and PCR. Calcium calmodulin dependent protein kinase II (CaMKII) and phosphorylated Ryanodine Receptor 2 (p-RyR2) expression were also investigated. Results: Stellate ganglionectomy significantly reduced myocardial hypertrophy and improved cardiac function, as indicated by decreased left ventricular posterior wall thickness (LVPWD) (p < 0.01), left ventricular end-diastolic diameter (LVEDD) and volume (p < 0.001), left ventricular end-diastolic volume (LVEDV) (p < 0.001), increased left ventricular ejection fraction (LVEF) (p < 0.001) and left ventricular fractional shortening (LVFS) (p < 0.001). Histological analysis confirmed reduced myocardial dilation. Molecular analysis revealed decreased CaMKII/RyR2 signaling (p < 0.001) and lower NE levels (p < 0.01), suggesting reduced neurohormonal stress. Conclusions: Stellate ganglionectomy alleviates hypertrophy and cardiac dysfunction caused by pressure overload, likely through inhibition of the CaMKII/RyR2 pathway, underscoring its potential as a therapeutic approach.
- 19 February 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (2) , 26268
Open AccessStellate Ganglionectomy Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction
Background: Enhanced cardiac sympathetic activity contributes to chronic heart failure (CHF). Interventions targeting the stellate ganglion (SG) can reduce this activity, potentially slowing the progression of cardiovascular diseases. This study examined the effects and mechanisms of stellate ganglionectomy on myocardial hypertrophy and cardiac dysfunction caused by pressure overload. Methods: A rat model of pressure overload was created using abdominal aortic constriction. Four groups were studied: the sham surgery, abdominal aortic coarctation (AB), aortic constriction plus left stellate ganglionectomy (LSG), and aortic constriction plus right stellate ganglionectomy (RSG) groups. Cardiac function was assessed via echocardiography, and myocardial hypertrophy and fibrosis were evaluated using hematoxylin-eosin staining (H&E) and Masson staining. Serum atrial natriuretic peptides (ANP) and norepinephrine (NE) levels were measured using enzyme linked immunosorbent assay (ELISA), and the levels of the molecular markers tyrosine hydroxylase (TH) and growth-associated protein-43 (GAP43) were analyzed using Western blotting and PCR. Calcium calmodulin dependent protein kinase II (CaMKII) and phosphorylated Ryanodine Receptor 2 (p-RyR2) expression were also investigated. Results: Stellate ganglionectomy significantly reduced myocardial hypertrophy and improved cardiac function, as indicated by decreased left ventricular posterior wall thickness (LVPWD) (p < 0.01), left ventricular end-diastolic diameter (LVEDD) and volume (p < 0.001), left ventricular end-diastolic volume (LVEDV) (p < 0.001), increased left ventricular ejection fraction (LVEF) (p < 0.001) and left ventricular fractional shortening (LVFS) (p < 0.001). Histological analysis confirmed reduced myocardial dilation. Molecular analysis revealed decreased CaMKII/RyR2 signaling (p < 0.001) and lower NE levels (p < 0.01), suggesting reduced neurohormonal stress. Conclusions: Stellate ganglionectomy alleviates hypertrophy and cardiac dysfunction caused by pressure overload, likely through inhibition of the CaMKII/RyR2 pathway, underscoring its potential as a therapeutic approach.
- 11 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (6) , 589
Successful diagnosis and surgical treatment of tuberculous pericarditis
- 11 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (6) , 589
Successful diagnosis and surgical treatment of tuberculous pericarditis
- 22 August 2023
- Published by Springer Nature in Current Medical Science
- Vol. 43 (5) , 979-987
Inhibitory Effect of PPARδ Agonist GW501516 on Proliferation of Hypoxia-induced Pulmonary Arterial Smooth Muscle Cells by Regulating the mTOR Pathway
Objective This study aimed to investigate the effects of the peroxisome proliferator-activated receptor δ (PPARδ) agonist GW501516 on the proliferation of pulmonary artery smooth muscle cells (PASMCs) induced by hypoxia, in order to search for new drugs for the treatment and prevention of pulmonary vascular remodeling. Methods PASMCs were incubated with different concentrations of GW501516 (10, 30, 100 nmol/L) under the hypoxic condition. The proliferation was determined by a CCK-8 assay. The cell cycle progression was analyzed by flow cytometry. The expression of PPARδ, S phase kinase-associated protein 2 (Skp2), and cell cycle-dependent kinase inhibitor p27 was detected by Western blotting. Then PASMCs were treated with 100 nmol/ L GW501516, 100 nmol/L mammalian target of rapamycin (mTOR) inhibitor rapamycin and/or 2 µmol/L mTOR activator MHY1485 to explore the molecular mechanisms by which GW501516 reduces the proliferation of PASMCs. Results The presented data demonstrated that hypoxia reduced the expression of PPARδ in an oxygen concentration- and time-dependent manner, and GW501516 decreased the proliferation of PASMCs induced by hypoxia by blocking the progression through the G0/G1 to S phase of the cell cycle. In accordance with these findings, GW501516 downregulated Skp2 and upregulated p27 in hypoxia-exposed PASMCs. Further experiments showed that rapamycin had similar effects as GW501516 in inhibiting cell proliferation, arresting the cell cycle, regulating the expression of Skp2 and p27, and inactivating mTOR in hypoxia-exposed PASMCs. Moreover, MHY1485 reversed all the beneficial effects of GW501516 on hypoxia-stimulated PASMCs. Conclusion GW501516 inhibited the proliferation of PASMCs induced by hypoxia through blocking the mTOR/Skp2/p27 signaling pathway.
- 22 August 2023
- Published by Springer Nature in Current Medical Science
- Vol. 43 (5) , 979-987
Inhibitory Effect of PPARδ Agonist GW501516 on Proliferation of Hypoxia-induced Pulmonary Arterial Smooth Muscle Cells by Regulating the mTOR Pathway
Objective This study aimed to investigate the effects of the peroxisome proliferator-activated receptor δ (PPARδ) agonist GW501516 on the proliferation of pulmonary artery smooth muscle cells (PASMCs) induced by hypoxia, in order to search for new drugs for the treatment and prevention of pulmonary vascular remodeling. Methods PASMCs were incubated with different concentrations of GW501516 (10, 30, 100 nmol/L) under the hypoxic condition. The proliferation was determined by a CCK-8 assay. The cell cycle progression was analyzed by flow cytometry. The expression of PPARδ, S phase kinase-associated protein 2 (Skp2), and cell cycle-dependent kinase inhibitor p27 was detected by Western blotting. Then PASMCs were treated with 100 nmol/ L GW501516, 100 nmol/L mammalian target of rapamycin (mTOR) inhibitor rapamycin and/or 2 µmol/L mTOR activator MHY1485 to explore the molecular mechanisms by which GW501516 reduces the proliferation of PASMCs. Results The presented data demonstrated that hypoxia reduced the expression of PPARδ in an oxygen concentration- and time-dependent manner, and GW501516 decreased the proliferation of PASMCs induced by hypoxia by blocking the progression through the G0/G1 to S phase of the cell cycle. In accordance with these findings, GW501516 downregulated Skp2 and upregulated p27 in hypoxia-exposed PASMCs. Further experiments showed that rapamycin had similar effects as GW501516 in inhibiting cell proliferation, arresting the cell cycle, regulating the expression of Skp2 and p27, and inactivating mTOR in hypoxia-exposed PASMCs. Moreover, MHY1485 reversed all the beneficial effects of GW501516 on hypoxia-stimulated PASMCs. Conclusion GW501516 inhibited the proliferation of PASMCs induced by hypoxia through blocking the mTOR/Skp2/p27 signaling pathway.
- Open Access
- 15 November 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 970036
Intestinal microbiota: A promising therapeutic target for hypertension
Hypertension has developed into an escalating serious global public health problem with multiple and unclear pathophysiological mechanisms. Recent studies have identified intestinal microbiota as a key perpetrator of hypertension through a variety of mechanisms. In this review, we highlight the potential roles of the intestinal microbiota and its metabolites in the development of hypertension, as well as the therapeutic potential for targeting intestinal microbiomes. We also shed light on the main limitations and challenges of the current research and suggest directions for future investigations. Finally, we discuss the development of accurate and personalized preventive and therapeutic strategies for hypotension by the modulation of intestinal microbes and metabolites.
- 15 November 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 970036
Open AccessIntestinal microbiota: A promising therapeutic target for hypertension
Hypertension has developed into an escalating serious global public health problem with multiple and unclear pathophysiological mechanisms. Recent studies have identified intestinal microbiota as a key perpetrator of hypertension through a variety of mechanisms. In this review, we highlight the potential roles of the intestinal microbiota and its metabolites in the development of hypertension, as well as the therapeutic potential for targeting intestinal microbiomes. We also shed light on the main limitations and challenges of the current research and suggest directions for future investigations. Finally, we discuss the development of accurate and personalized preventive and therapeutic strategies for hypotension by the modulation of intestinal microbes and metabolites.
- Open Access
- 26 October 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 984087
mRNA, lncRNA, and circRNA expression profiles in a new aortic dissection murine model induced by hypoxia and Ang II
Background and aims: Aortic dissection (AD) is a cardiovascular emergency with degeneration of the aortic media. Mounting evidence indicates obstructive sleep apnea (OSA) as an independent risk factor for AD development with unknown mechanisms. This study aims to establish a stable murine model of OSA-related AD (OSA-AD) and uncover the potential changes in gene transcripts in OSA-AD.Materials and methods: ApoE–/–mice were exposed to the chronic intermittent hypoxia (CIH) system combined with Ang II administration to establish the OSA-AD model. Pathological staining was performed to exhibit the physiological structure of the mouse aorta. The SBC mouse ceRNA microarray was used to identify significantly differentially expressed (DE) mRNAs, DE long-non-coding RNAs (DElncRNAs), and DE circular RNAs (DEcircRNAs) in OSA-AD tissues. Subsequently, bioinformatics analysis, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genome (KEGG), and protein–protein interaction (PPI) analyses, were performed to evaluate the function of the significantly differentially expressed transcripts (DETs). The hub genes were confirmed using quantitative real-time polymerase chain reaction (qRT-PCR).Results: ApoE–/–mice exposed to CIH and Ang II showed a high ratio of aortic accident (73.33%) and significant aortic diameter dilatation (1.96 ± 0.175 mm). A total of 1,742 mRNAs, 2,625 lncRNAs, and 537 circRNAs were identified as DETs (LogFC ≥ 1.5 or ≤ –1.5,P< 0.05). GO and KEGG analyses demonstrated that the differentially expressed mRNAs (DEmRNAs) were most enriched in cell proliferation, migration, apoptosis, inflammation, and hypoxia-related terms, which are closely related to aortic structural homeostasis. The PPI network contained 609 nodes and 934 connections, the hub genes were highlighted with the CytoHubba plugin and confirmed by qRT-PCR in AD tissues. KEGG pathway analysis revealed that thecis-regulated genes of DElncRNAs and circRNAs-host genes were enriched in aortic structural homeostasis-related pathways.Conclusion: Our findings help establish ade novoOSA-AD animal model using ApoE–/–mice. Many DEmRNAs, DElncRNAs, and DEcircRNAs were screened for the first time in OSA-AD tissues. Our findings provide useful bioinformatics data for understanding the molecular mechanism of OSA-AD and developing potential therapeutic strategies for OSA-AD.
- 26 October 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 984087
Open AccessmRNA, lncRNA, and circRNA expression profiles in a new aortic dissection murine model induced by hypoxia and Ang II
Background and aims: Aortic dissection (AD) is a cardiovascular emergency with degeneration of the aortic media. Mounting evidence indicates obstructive sleep apnea (OSA) as an independent risk factor for AD development with unknown mechanisms. This study aims to establish a stable murine model of OSA-related AD (OSA-AD) and uncover the potential changes in gene transcripts in OSA-AD.Materials and methods: ApoE–/–mice were exposed to the chronic intermittent hypoxia (CIH) system combined with Ang II administration to establish the OSA-AD model. Pathological staining was performed to exhibit the physiological structure of the mouse aorta. The SBC mouse ceRNA microarray was used to identify significantly differentially expressed (DE) mRNAs, DE long-non-coding RNAs (DElncRNAs), and DE circular RNAs (DEcircRNAs) in OSA-AD tissues. Subsequently, bioinformatics analysis, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genome (KEGG), and protein–protein interaction (PPI) analyses, were performed to evaluate the function of the significantly differentially expressed transcripts (DETs). The hub genes were confirmed using quantitative real-time polymerase chain reaction (qRT-PCR).Results: ApoE–/–mice exposed to CIH and Ang II showed a high ratio of aortic accident (73.33%) and significant aortic diameter dilatation (1.96 ± 0.175 mm). A total of 1,742 mRNAs, 2,625 lncRNAs, and 537 circRNAs were identified as DETs (LogFC ≥ 1.5 or ≤ –1.5,P< 0.05). GO and KEGG analyses demonstrated that the differentially expressed mRNAs (DEmRNAs) were most enriched in cell proliferation, migration, apoptosis, inflammation, and hypoxia-related terms, which are closely related to aortic structural homeostasis. The PPI network contained 609 nodes and 934 connections, the hub genes were highlighted with the CytoHubba plugin and confirmed by qRT-PCR in AD tissues. KEGG pathway analysis revealed that thecis-regulated genes of DElncRNAs and circRNAs-host genes were enriched in aortic structural homeostasis-related pathways.Conclusion: Our findings help establish ade novoOSA-AD animal model using ApoE–/–mice. Many DEmRNAs, DElncRNAs, and DEcircRNAs were screened for the first time in OSA-AD tissues. Our findings provide useful bioinformatics data for understanding the molecular mechanism of OSA-AD and developing potential therapeutic strategies for OSA-AD.
- Open Access
- 15 February 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
-308G/A polymorphism of tumor necrosis factor alpha (TNF-α) gene and metabolic syndrome susceptibility: a meta-analysis
Many studies tried to assess the relationship between -308G/A polymorphism of tumor necrosis factor alpha (TNF-α) gene and risk of metabolic syndrome (MS), but their results were contradictory. This meta-analysis aimed to precisely evaluate this association. A systematic literature search was performed in Pubmed database and WanFang Med Online, STATA software 14.0 was used for the meta-analysis. Eleven independent studies containing 3277 cases and 3312 controls were included in our meta-analysis. In overall analysis, significant association was found between -308G/A polymorphism of TNF-α and MS in both allele model (OR 1.47, 95% CI 1.09–1.98, P 0.013) and dominant model (OR 1.77, 95% CI 1.21–2.58, P 0.003). In the subgroup analysis, the A allele was associated with increased risk of MS in Asia group (allele model: OR 1.82 95% CI 1.31–2.53, P < 0.001; dominant model: OR 2.30, 95% CI 1.64–3.21 P < 0.001; homozygous model: OR 2.29, 95% CI 1.31–4.01, P 0.004), and decreased risk of MS in Europe group (dominant model: OR 0.83, 95% CI 0.70–0.99, P < 0.001; recessive model: OR 0.51, 95% CI 0.28–0.92, P 0.025; homozygous model: OR 0.49 95% CI 0.27–0.89, P 0.02). The A allele also appeared to linked to increased risk of MS in CDS group and IDF groups. No significant association was observed in NCEPATPIII group. Our results suggested that -308G/A of TNF-α gene was a risk factor for MS, but it may played different roles in different ethnics, further studies with larger sample size and more other ethnics should be performed to confirm our conclusions.
- 15 February 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
Open Access-308G/A polymorphism of tumor necrosis factor alpha (TNF-α) gene and metabolic syndrome susceptibility: a meta-analysis
Many studies tried to assess the relationship between -308G/A polymorphism of tumor necrosis factor alpha (TNF-α) gene and risk of metabolic syndrome (MS), but their results were contradictory. This meta-analysis aimed to precisely evaluate this association. A systematic literature search was performed in Pubmed database and WanFang Med Online, STATA software 14.0 was used for the meta-analysis. Eleven independent studies containing 3277 cases and 3312 controls were included in our meta-analysis. In overall analysis, significant association was found between -308G/A polymorphism of TNF-α and MS in both allele model (OR 1.47, 95% CI 1.09–1.98, P 0.013) and dominant model (OR 1.77, 95% CI 1.21–2.58, P 0.003). In the subgroup analysis, the A allele was associated with increased risk of MS in Asia group (allele model: OR 1.82 95% CI 1.31–2.53, P < 0.001; dominant model: OR 2.30, 95% CI 1.64–3.21 P < 0.001; homozygous model: OR 2.29, 95% CI 1.31–4.01, P 0.004), and decreased risk of MS in Europe group (dominant model: OR 0.83, 95% CI 0.70–0.99, P < 0.001; recessive model: OR 0.51, 95% CI 0.28–0.92, P 0.025; homozygous model: OR 0.49 95% CI 0.27–0.89, P 0.02). The A allele also appeared to linked to increased risk of MS in CDS group and IDF groups. No significant association was observed in NCEPATPIII group. Our results suggested that -308G/A of TNF-α gene was a risk factor for MS, but it may played different roles in different ethnics, further studies with larger sample size and more other ethnics should be performed to confirm our conclusions.
- Open Access
Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study
Background: Since December 2019, a cluster of coronavirus disease 2019 (COVID-19) occurred in Wuhan, Hubei Province, China and spread rapidly from China to other countries. In-hospital mortality are high in severe cases and cardiac injury characterized by elevated cardiac troponin are common among them. The mechanism of cardiac injury and the relationship between cardiac injury and in-hospital mortality remained unclear. Studies focused on cardiac injury in COVID-19 patients are scarce. Objectives: To investigate the association between cardiac injury and in-hospital mortality of patients with confirmed or suspected COVID-19. Methods: Demographic, clinical, treatment, and laboratory data of consecutive confirmed or suspected COVID-19 patients admitted in Wuhan No.1 Hospital from 25 th December, 2019 to 15 th February, 2020 were extracted from electronic medical records and were retrospectively reviewed and analyzed. Univariate and multivariate Cox regression analysis were used to explore the risk factors associated with in-hospital death. Results: A total of 110 patients with confirmed (n=80) or suspected (n=30) COVID-19 were screened and 48 patients (female 31.3%, mean age 70.58±13.38 year old) among them with high-sensitivity cardiac troponin I (hs-cTnI) test within 48 hours after admission were included, of whom 17 (17/48, 35.4%) died in hospital while 31 (31/48, 64.6%) were discharged or transferred to other hospital. High-sensitivity cardiac troponin I was elevated in 13 (13/48, 27.1%) patents. Multivariate Cox regression analysis showed pulse oximetry of oxygen saturation (SpO 2 ) on admission (HR 0.704, 95% CI 0.546-0.909, per 1% decrease, p=0.007), elevated hs-cTnI (HR 10.902, 95% 1.279-92.927, p=0.029) and elevated d-dimer (HR 1.103, 95%CI 1.034-1.176, per 1mg/L increase, p=0.003) on admission were independently associated with in-hospital mortality. Conclusions: Cardiac injury defined by hs-cTnI elevation and elevated d-dimer on admission were risk factors for in-hospital death, while higher SpO 2 could be seen as a protective factor, which could help clinicians to identify patients with adverse outcome at the early stage of COVID-19.
Open AccessMyocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study
Background: Since December 2019, a cluster of coronavirus disease 2019 (COVID-19) occurred in Wuhan, Hubei Province, China and spread rapidly from China to other countries. In-hospital mortality are high in severe cases and cardiac injury characterized by elevated cardiac troponin are common among them. The mechanism of cardiac injury and the relationship between cardiac injury and in-hospital mortality remained unclear. Studies focused on cardiac injury in COVID-19 patients are scarce. Objectives: To investigate the association between cardiac injury and in-hospital mortality of patients with confirmed or suspected COVID-19. Methods: Demographic, clinical, treatment, and laboratory data of consecutive confirmed or suspected COVID-19 patients admitted in Wuhan No.1 Hospital from 25 th December, 2019 to 15 th February, 2020 were extracted from electronic medical records and were retrospectively reviewed and analyzed. Univariate and multivariate Cox regression analysis were used to explore the risk factors associated with in-hospital death. Results: A total of 110 patients with confirmed (n=80) or suspected (n=30) COVID-19 were screened and 48 patients (female 31.3%, mean age 70.58±13.38 year old) among them with high-sensitivity cardiac troponin I (hs-cTnI) test within 48 hours after admission were included, of whom 17 (17/48, 35.4%) died in hospital while 31 (31/48, 64.6%) were discharged or transferred to other hospital. High-sensitivity cardiac troponin I was elevated in 13 (13/48, 27.1%) patents. Multivariate Cox regression analysis showed pulse oximetry of oxygen saturation (SpO 2 ) on admission (HR 0.704, 95% CI 0.546-0.909, per 1% decrease, p=0.007), elevated hs-cTnI (HR 10.902, 95% 1.279-92.927, p=0.029) and elevated d-dimer (HR 1.103, 95%CI 1.034-1.176, per 1mg/L increase, p=0.003) on admission were independently associated with in-hospital mortality. Conclusions: Cardiac injury defined by hs-cTnI elevation and elevated d-dimer on admission were risk factors for in-hospital death, while higher SpO 2 could be seen as a protective factor, which could help clinicians to identify patients with adverse outcome at the early stage of COVID-19.